Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma

Hong Zhang, Kristen Spencer, Stephen K. Burley, X. F.Steven Zheng

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and a leading cause of cancer deaths worldwide. HCC is a male-dominant cancer with a male:female ratio of up to 7:1. The androgen receptor (AR) is the male hormone receptor known as a major oncogenic driver of prostate cancer. Although AR has been linked to the sexual dimorphism of HCC, clinical trials with AR-targeted agents failed to generate survival benefits. Recent studies provide new insights into the role of AR in liver tumorigenesis and therapeutic responses. Herein, we review current understanding of AR signaling in HCC and feedback mechanisms that limit response to AR blockade. New AR-targeting strategies that might improve outcomes in HCC therapies are also discussed.

Original languageEnglish (US)
JournalDrug Discovery Today
StateAccepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this